No Cover Image

Journal article 379 views 49 downloads

Organoids with a Type 1 Collagen Scaffold to Model Bacterial Cancer Therapy

Lydia Farrell Orcid Logo, Cleo Bonnet, Alethea Tang, Sev Peneva, Non G. Williams Orcid Logo, Sunil Dolwani, Lee Parry Orcid Logo, Paul Dyson Orcid Logo

Cells, Volume: 14, Issue: 7, Start page: 524

Swansea University Authors: Lydia Farrell Orcid Logo, Alethea Tang, Sev Peneva, Paul Dyson Orcid Logo

  • 69267.VoR.pdf

    PDF | Version of Record

    © 2025 by the authors. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license.

    Download (11.33MB)

Check full text

DOI (Published version): 10.3390/cells14070524

Abstract

Bacterial cancer therapy (BCT) is emerging as an important option for the treatment of solid tumours, with promising outcomes in preclinical trials. Further progress is hampered by an incomplete understanding of how oncotropic bacteria, such as attenuated strains of Salmonella enterica serovar Typhi...

Full description

Published in: Cells
ISSN: 2073-4409
Published: MDPI AG 2025
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa69267
first_indexed 2025-04-10T13:56:16Z
last_indexed 2025-05-24T11:24:08Z
id cronfa69267
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2025-05-23T12:55:03.3253439</datestamp><bib-version>v2</bib-version><id>69267</id><entry>2025-04-10</entry><title>Organoids with a Type 1 Collagen Scaffold to Model Bacterial Cancer Therapy</title><swanseaauthors><author><sid>13cc2d4d6ef6f4094c4f8df0b217dd58</sid><ORCID>0000-0002-7643-6009</ORCID><firstname>Lydia</firstname><surname>Farrell</surname><name>Lydia Farrell</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>6650ebd828f3596d5da522ebd2c8b51d</sid><firstname>Alethea</firstname><surname>Tang</surname><name>Alethea Tang</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>de5fddba66c43de0d92f52f30a5c98de</sid><firstname>Sev</firstname><surname>Peneva</surname><name>Sev Peneva</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>300e3f46b70ae83f563b24f41d00cd17</sid><ORCID>0000-0002-0558-2666</ORCID><firstname>Paul</firstname><surname>Dyson</surname><name>Paul Dyson</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2025-04-10</date><deptcode>MEDS</deptcode><abstract>Bacterial cancer therapy (BCT) is emerging as an important option for the treatment of solid tumours, with promising outcomes in preclinical trials. Further progress is hampered by an incomplete understanding of how oncotropic bacteria, such as attenuated strains of Salmonella enterica serovar Typhimurium, colonise tumours and the responses of both the bacteria and tumour cells to this colonisation. To model this, we developed organoids that are permissive for bacterial colonisation, replacing the conventional commercially available extracellular matrix (e.g., Matrigel) with a type I collagen matrix scaffold. A comparison of the two extracellular matrices indicated that type 1 collagen permitted an initial infection efficiency more than 5-times greater than with Matrigel. In addition, subsequent growth within type 1 collagen expanded bacterial cell numbers by over 10-fold within 4 days of infection. These organoids allow for the visualisation of bacterial chemoattraction, cell invasion and subsequent population of the interior lumen, and will permit the future optimisation of BCT. In addition, by establishing patient-derived organoids, we demonstrate a platform for developing future personalised treatments exploiting BCT.</abstract><type>Journal Article</type><journal>Cells</journal><volume>14</volume><journalNumber>7</journalNumber><paginationStart>524</paginationStart><paginationEnd/><publisher>MDPI AG</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>2073-4409</issnElectronic><keywords>bacterial cancer therapy; organoid; Salmonella enterica serovar Typhimurium; personalised medicine; type 1 collagen</keywords><publishedDay>1</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2025</publishedYear><publishedDate>2025-04-01</publishedDate><doi>10.3390/cells14070524</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>This research was funded by grants from Cancer Research UK (reference: C23498/A27517) to L.P., S.D. and P.D. and the Research Wales Innovation Fund (reference R3-EEF43) to P.D.</funders><projectreference/><lastEdited>2025-05-23T12:55:03.3253439</lastEdited><Created>2025-04-10T14:53:45.4512868</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Lydia</firstname><surname>Farrell</surname><orcid>0000-0002-7643-6009</orcid><order>1</order></author><author><firstname>Cleo</firstname><surname>Bonnet</surname><order>2</order></author><author><firstname>Alethea</firstname><surname>Tang</surname><order>3</order></author><author><firstname>Sev</firstname><surname>Peneva</surname><order>4</order></author><author><firstname>Non G.</firstname><surname>Williams</surname><orcid>0000-0002-1778-3967</orcid><order>5</order></author><author><firstname>Sunil</firstname><surname>Dolwani</surname><order>6</order></author><author><firstname>Lee</firstname><surname>Parry</surname><orcid>0000-0002-4467-9196</orcid><order>7</order></author><author><firstname>Paul</firstname><surname>Dyson</surname><orcid>0000-0002-0558-2666</orcid><order>8</order></author></authors><documents><document><filename>69267__34342__7d5227f9cb6c405a86779512f861e334.pdf</filename><originalFilename>69267.VoR.pdf</originalFilename><uploaded>2025-05-23T12:52:30.1275842</uploaded><type>Output</type><contentLength>11876051</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2025 by the authors. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2025-05-23T12:55:03.3253439 v2 69267 2025-04-10 Organoids with a Type 1 Collagen Scaffold to Model Bacterial Cancer Therapy 13cc2d4d6ef6f4094c4f8df0b217dd58 0000-0002-7643-6009 Lydia Farrell Lydia Farrell true false 6650ebd828f3596d5da522ebd2c8b51d Alethea Tang Alethea Tang true false de5fddba66c43de0d92f52f30a5c98de Sev Peneva Sev Peneva true false 300e3f46b70ae83f563b24f41d00cd17 0000-0002-0558-2666 Paul Dyson Paul Dyson true false 2025-04-10 MEDS Bacterial cancer therapy (BCT) is emerging as an important option for the treatment of solid tumours, with promising outcomes in preclinical trials. Further progress is hampered by an incomplete understanding of how oncotropic bacteria, such as attenuated strains of Salmonella enterica serovar Typhimurium, colonise tumours and the responses of both the bacteria and tumour cells to this colonisation. To model this, we developed organoids that are permissive for bacterial colonisation, replacing the conventional commercially available extracellular matrix (e.g., Matrigel) with a type I collagen matrix scaffold. A comparison of the two extracellular matrices indicated that type 1 collagen permitted an initial infection efficiency more than 5-times greater than with Matrigel. In addition, subsequent growth within type 1 collagen expanded bacterial cell numbers by over 10-fold within 4 days of infection. These organoids allow for the visualisation of bacterial chemoattraction, cell invasion and subsequent population of the interior lumen, and will permit the future optimisation of BCT. In addition, by establishing patient-derived organoids, we demonstrate a platform for developing future personalised treatments exploiting BCT. Journal Article Cells 14 7 524 MDPI AG 2073-4409 bacterial cancer therapy; organoid; Salmonella enterica serovar Typhimurium; personalised medicine; type 1 collagen 1 4 2025 2025-04-01 10.3390/cells14070524 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Another institution paid the OA fee This research was funded by grants from Cancer Research UK (reference: C23498/A27517) to L.P., S.D. and P.D. and the Research Wales Innovation Fund (reference R3-EEF43) to P.D. 2025-05-23T12:55:03.3253439 2025-04-10T14:53:45.4512868 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Lydia Farrell 0000-0002-7643-6009 1 Cleo Bonnet 2 Alethea Tang 3 Sev Peneva 4 Non G. Williams 0000-0002-1778-3967 5 Sunil Dolwani 6 Lee Parry 0000-0002-4467-9196 7 Paul Dyson 0000-0002-0558-2666 8 69267__34342__7d5227f9cb6c405a86779512f861e334.pdf 69267.VoR.pdf 2025-05-23T12:52:30.1275842 Output 11876051 application/pdf Version of Record true © 2025 by the authors. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) license. true eng https://creativecommons.org/licenses/by/4.0/
title Organoids with a Type 1 Collagen Scaffold to Model Bacterial Cancer Therapy
spellingShingle Organoids with a Type 1 Collagen Scaffold to Model Bacterial Cancer Therapy
Lydia Farrell
Alethea Tang
Sev Peneva
Paul Dyson
title_short Organoids with a Type 1 Collagen Scaffold to Model Bacterial Cancer Therapy
title_full Organoids with a Type 1 Collagen Scaffold to Model Bacterial Cancer Therapy
title_fullStr Organoids with a Type 1 Collagen Scaffold to Model Bacterial Cancer Therapy
title_full_unstemmed Organoids with a Type 1 Collagen Scaffold to Model Bacterial Cancer Therapy
title_sort Organoids with a Type 1 Collagen Scaffold to Model Bacterial Cancer Therapy
author_id_str_mv 13cc2d4d6ef6f4094c4f8df0b217dd58
6650ebd828f3596d5da522ebd2c8b51d
de5fddba66c43de0d92f52f30a5c98de
300e3f46b70ae83f563b24f41d00cd17
author_id_fullname_str_mv 13cc2d4d6ef6f4094c4f8df0b217dd58_***_Lydia Farrell
6650ebd828f3596d5da522ebd2c8b51d_***_Alethea Tang
de5fddba66c43de0d92f52f30a5c98de_***_Sev Peneva
300e3f46b70ae83f563b24f41d00cd17_***_Paul Dyson
author Lydia Farrell
Alethea Tang
Sev Peneva
Paul Dyson
author2 Lydia Farrell
Cleo Bonnet
Alethea Tang
Sev Peneva
Non G. Williams
Sunil Dolwani
Lee Parry
Paul Dyson
format Journal article
container_title Cells
container_volume 14
container_issue 7
container_start_page 524
publishDate 2025
institution Swansea University
issn 2073-4409
doi_str_mv 10.3390/cells14070524
publisher MDPI AG
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 1
active_str 0
description Bacterial cancer therapy (BCT) is emerging as an important option for the treatment of solid tumours, with promising outcomes in preclinical trials. Further progress is hampered by an incomplete understanding of how oncotropic bacteria, such as attenuated strains of Salmonella enterica serovar Typhimurium, colonise tumours and the responses of both the bacteria and tumour cells to this colonisation. To model this, we developed organoids that are permissive for bacterial colonisation, replacing the conventional commercially available extracellular matrix (e.g., Matrigel) with a type I collagen matrix scaffold. A comparison of the two extracellular matrices indicated that type 1 collagen permitted an initial infection efficiency more than 5-times greater than with Matrigel. In addition, subsequent growth within type 1 collagen expanded bacterial cell numbers by over 10-fold within 4 days of infection. These organoids allow for the visualisation of bacterial chemoattraction, cell invasion and subsequent population of the interior lumen, and will permit the future optimisation of BCT. In addition, by establishing patient-derived organoids, we demonstrate a platform for developing future personalised treatments exploiting BCT.
published_date 2025-04-01T05:27:43Z
_version_ 1851097836347719680
score 11.089407

Similar Items